AstraZeneca COVID-19 vaccine: review of very rare cases of unusual blood clots continues
EMA’s safety committee has met to discuss ongoing review of very rare cases of unusual blood clots linked to low numbers of platelets, in people vaccinated with AZ’s COVID-19 vaccine (now called Vaxzevria). At present, no specific risk factors or causal link have been identified.
Source:
European Medicines Agency
SPS commentary:
As communicated on 18 March, European Medicines Agency is of the view that the benefits of the AstraZeneca vaccine in preventing COVID-19, with its associated risk of hospitalisation and death, outweigh the risks of side effects.